How digital medicine is reshaping the conversation around Portugal’s “Golden Visa”

Healthcare systems worldwide are facing mounting pressure: populations are aging, the share of chronic conditions continues to rise, and the post-COVID demand that hasn’t gone away is gradually pushing infrastructure to its limits.

According to the World Health Organization, musculoskeletal disorders affect more than 2 billion people globally. At the same time, critical challenges remain unresolved—mental health, cardiovascular disease, and access to primary care in both developed and developing countries.

The cost is high: delays in diagnosis, overburdened clinicians, and millions of patients who never receive the care they need. The question now sounds different—who will fund the transformation of healthcare, and can private capital help close the gap.

This is where investment and social responsibility intersect.

Digital health as a global investment trend

In recent years, investment in digital health and MedTech has accelerated. The overall market estimate for digital healthcare in 2025 is around $427 billion, with growth expected to exceed 21% annually on average. Meanwhile, the AI in healthcare segment is forecast to grow from $15.1 billion in 2022 to more than $187 billion by 2030—roughly 37% per year.

Venture investors increasingly view tech-enabled healthcare—from AI diagnostics to digital therapeutics—as both a structural growth opportunity and a real benefit to society.

Earlier, the approaches of “investing for impact” versus “investing for returns” were often treated as opposites. Today, that line is blurring: capital flowing into healthcare innovation delivers more than financial outcomes. It reduces suffering, extends lives, eases strain on public systems, and improves care quality for people who might otherwise go without treatment. When technologies are selected well, the social “multiplier” can be genuinely significant.

Why Portugal is becoming a launchpad for HealthTech and MedTech

Portugal is steadily positioning itself among Europe’s most promising places to launch innovations. The country has a strong academic and research base, competitive operating costs, and meaningful government support for healthcare technology.

The results confirm that the direction is right. For example, a Portuguese company founded in 2015 developed AI-driven approaches to digital physical therapy for musculoskeletal conditions and reached an evaluation of around $4 billion, becoming Portugal’s first “medical unicorn.” The technology has already helped hundreds of thousands of patients manage chronic pain and recover from injuries without the constant need for expensive in-person interventions—reducing pressure on healthcare systems and improving clinical outcomes.

Another example is a telemedicine platform that creates an integrated set of tools for both patients and healthcare professionals. It helps build personalized care pathways in a digital format, ensuring access to high-quality treatment regardless of geography and socio-economic factors.

These stories are not isolated. They reflect a growing ecosystem where innovation is created not only for business, but also to address the most urgent health challenges.

Portugal’s “Golden Visa”: the focus shifts from real estate to investment

For international investors, Portugal is also attractive due to its Golden Visa program. Historically, a large share of discussions centered on real estate. However, after reforms removed the real-estate investment route, the key mechanism for obtaining residency through investment has become a model based on regulated investment funds.

The minimum investment amount to participate in the Golden Visa program via investment funds is €500,000. Funds must be regulated and operate in line with requirements from CMVM (the Portuguese Securities Market Commission), while investing mainly in Portuguese companies.

It’s important to understand this: for the “right” investor, residency remains valuable—but increasingly it becomes a secondary factor. The focus is shifting to impact: contributing to more sustainable and accessible healthcare.

This shift makes room for more meaningful investments.

RYSE Golden Opportunities Fund: residency as a result of investing in clinical outcomes

A recent joint venture between RYSE and experienced Portuguese asset manager Fundbox—the launch of the RYSE Golden Opportunities Fund—illustrates exactly this evolution.

RYSE (founded in 2017, headquartered in London) is a venture fund focused on innovation in HealthTech and MedTech. RYSE investors back early- and growth-stage projects tackling global healthcare challenges—ranging from digital diagnostics and therapeutic solutions to medical devices and health AI.

The fund is structured according to Portugal’s Golden Visa program requirements: investors receive legal residency through a pathway linked to a regulated investment fund. But the value proposition goes beyond the process itself.

Each company in the portfolio is assessed not only for commercial potential, but also for its ability to create measurable clinical impact at scale: reducing readmissions, improving early diagnosis, expanding access to specialist care, and lowering system costs that increasingly strain public health budgets.

While previous generations of Golden Visa investors often sought real-estate ownership and residency rights, the RYSE Golden Opportunities Fund offers a different approach: the ability to direct capital to companies that reduce pressure on healthcare systems around the world, while gaining residency in Portugal and building a longer-term path toward access to the EU.

Residency truly matters. But it’s the “legacy” of the investment that distinguishes this model.

Clinical validation of the thesis and partnerships with industry

RYSE’s investment thesis is grounded in practical clinical impact. Previously, the fund collaborated with NHS England through public-private initiatives aimed at identifying technologies that could improve operational efficiency, reduce financial burden, and expand access to healthcare in real-world service settings.

RYSE continues to engage with major healthcare players: global pharma companies (including Novartis), leading medical device manufacturers (such as Medtronic), European and US insurers, as well as healthcare organizations across the UK, GCC countries, and the United States.

These partnerships help validate the clinical relevance of portfolio solutions and partially reduce risks commonly associated with early-stage investing. Unlike “pure” technology funds, RYSE gains additional entry points for adoption and evidence-based piloting.

Why this matters to high-net-worth investors

For high-capital investors who want investments to deliver not only passive income but also deeper meaning, this is a timely shift in focus.

Yes, residency in Portugal and access to the EU are meaningful advantages. But the bigger opportunity is to participate in funding solutions to one of the defining problems of our time: the shortage of effective, accessible healthcare.

Residency as a “byproduct” of supporting the next generation of medical innovations is fundamentally different from how the Golden Visa story has traditionally been framed. Here, a personal mobility strategy is tied to a clear, long-term global impact.

As institutional investors increasingly turn their attention to digital medicine, early exposure to the sector through tools like the RYSE Golden Opportunities Fund can deliver more than financial results—creating a long-term legacy measured not only by returns, but also by better lives, stronger systems, and a healthier world, step by step.

For more information about the RYSE Golden Opportunities Fund and the participation terms for the Portugal Golden Visa, contact Windsor Capital Management via the website.

If you’re considering the Golden Visa in Portugal, it’s worth looking beyond the paperwork and requirements. Today, more and more investors connect immigration decisions with long-term social impact. The rise of digital health and MedTech is reshaping how healthcare initiatives are funded—so investments can be about both status and real value for the country. Want help aligning your plan with your goals and budget? Explore our Golden Visa resources.

Our Telegram channel about various types of Greek residence permits, digital nomad programs, and the Greek Golden Visa: @digitalnomadgr